Professor Dr. Nwabueze Patrick Okechukwu

Professor Dr. Nwabueze Patrick Okechukwu is an internationally accomplished pharmacologist and drug discovery expert whose career reflects more than 20 years of scientific leadership, innovation, and measurable research impact. As Principal Drug Discovery Researcher at ZeeRick Medisciences Sdn Bhd, he drives the company’s scientific vision, guiding the development of next-generation therapeutics and evidence-based healthcare solutions positioned for global relevance.

A U.S.-trained Clinical Research Trial Professional, Professor Patrick brings deep expertise in translational science—successfully bridging laboratory discovery with clinical application. He currently serves on the Faculty of Internal Medicine at the Charles R. Drew University of Medicine and Science in Los Angeles and holds a Professorship in Pharmacology at Capital City University, underscoring his global academic standing and influence.

Research Portfolio & Mentorship:
Professor Patrick has built a distinguished research portfolio that includes over 80 peer-reviewed publications, more than 70 international conference presentations, and leadership roles as Principal and Co-Principal Investigator on multiple funded research projects. He has mentored and supervised over 190 research scholars, contributing significantly to the development of future scientific talent.

Clinical Focus:
His research focuses on high-impact therapeutic areas, including drug discovery targeting diabetes and its complications, inflammatory disorders, bone fragility, advanced wound healing, and Alzheimer’s disease. With specialized expertise in both insulin-dependent and insulin-independent pathways, and the core relationship between Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s Disease (AD), his work supports the creation of safer, more effective treatments designed to meet urgent and growing global healthcare demands.

Strategic Leadership at ZeeRick Medisciences:
Professor Patrick provides strategic scientific leadership across the innovation pipeline—from early-stage research to product development and commercialization. His stewardship strengthens the company’s position in pharmaceuticals, science-backed botanical therapeutics, nutraceuticals, functional nutrition, biomedical technologies, and advanced medical devices. ZeeRick Medisciences is also the product registration holder and owner of PlasGluCon®, reflecting its commitment to quality, regulatory excellence, and market readiness.